Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous EBV-specific CTLs in Early MS
NCT02912897Phase 1Recruiting
- Sponsor
- CHU de Nantes
- Start
- Jan 2021
- Primary completion
- Nov 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous Epstein-Barr virus-specific cytotoxic T lymphocytes in multiple sclerosis (MS), sponsored by CHU de Nantes. Primary endpoint: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE at 2 years. Started Jan 2021; status: recruiting.
02
Drugs
autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02912897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912897.